文献类型：期刊文献

英文题名：MicroRNA-92a regulates the development of cutaneous malignant melanoma by mediating FOXP1

作者：Sun, H-W[1];Yang, G-L[2];Wang, S-N[3];Zhang, Y-J[1];Ding, J-X[1];Zhang, X-N[4]

第一作者：Sun, H-W

通信作者：Yang, GL[1]

机构：[1]Peoples Hosp Pingliang, Dept Dermatol, Pingliang, Peoples R China;[2]Southern Med Univ, Shenzhen Hosp, Dept Skin Beauty, Shenzhen, Peoples R China;[3]Gansu Univ Chinese Med, Affiliated Hosp, Dept Dermatol, Lanzhou, Gansu, Peoples R China;[4]Peoples Hosp Zhouzhi Cty, Dept Dermatol, Xian, Shaanxi, Peoples R China

第一机构：Peoples Hosp Pingliang, Dept Dermatol, Pingliang, Peoples R China

通信机构：[1]corresponding author), Southern Med Univ, Shenzhen Hosp, Dept Skin Beauty, Shenzhen, Peoples R China.

年份：2019

卷号：23

期号：20

起止页码：8991

外文期刊名：EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES

收录：;Scopus(收录号：2-s2.0-85074733325);WOS:【SCI-EXPANDED(收录号:WOS:000495355200033)】；

语种：英文

外文关键词：MicroRNA-92a; FOXP1; CMM; Proliferation

摘要：OBJECTIVE: MicroRNAs are noncoding RNAs which are involved in the occurrence and progression of tumors. This study aims to explore the role of microRNA-92a in cutaneous malignant melanoma (CMM) and its underlying mechanism. PATIENTS AND METHODS: The expression level of microRNA-92a in 75 pairs of CMM tissues and paracancerous tissues was determined using quantitative Real Time-Polymerase Chain Reaction (qRT-PCR). The correlation between microRNA-92a expression with clinical data of CMM patients was analyzed. Besides, microRNA-92a expression in CMM cells and primary epidermal melanocytes (PEM) was determined by qRT-PCR as well. After transfection of si-microRNA-92a in CMM cells, biological performances of CMM were determined using cell counting kit-8 (CCK-8), colony formation and transwell assay, respectively. FOXP1 expression in CMM cells and tissues was determined using Western blot. Kaplan-Meier survival curves were drawn to explore the correlation between the FOXP1 expression and prognosis of CMM patients. RESULTS: MicroRNA-92a was highly expressed in CMM tissues compared with that of paracancerous tissues. Compared with CMM patients with lower expression of microRNA-92a, those with higher expression of microRNA-92a presented higher tumor stage, higher incidences of lymph node metastasis and distant metastasis, as well as lower overall survival. The knockdown of microRNA-92a remarkably decreased proliferative, invasive and metastatic capacities of CMM cells. Western blot results elucidated that microRNA-92a knockdown in CMM cells upregulates FOXP1 expression. Additionally, rescue experiments showed that mi-croRNA-92a regulates biological performances of CMM cells by regulating FOXP1. CONCLUSIONS: MicroRNA-92a is highly expressed in CMM, which is remarkably correlated to tumor stage and poor prognosis of CMM patients. We found that microRNA-92a pro-motes malignant progression of CMM by regulating FOXP1.